Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears AutoGenomics' CYP2C19 Assay

This article has been updated to clarify the intended use of the assay.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AutoGenomics today said that the US Food and Drug Administration has given 510(k) clearance for its Infiniti CYP2C19 assay.

The test detects three genetic variants, *2, *3, and *17 of the CYP450 2C19 gene. The test is for use on AutoGenomics' Infiniti Analyzer molecular diagnostic platform.

Though the label for the test does not specifically state that the assay will be used as an aid for Plavix (clopidogrel) dosing, it is expected to be used for that purpose.

In a statement, Fareed Kureshy, president and CEO of AutoGenomics, called the FDA decision "an important milestone in the era of personalized medicine," and added that several of the company's customers have been awaiting such regulatory clearance to implement testing in their practice.

Robert Cole, Chief Medical Officer for the Vista, Calif.-based firm, said that the test is unique in evaluating *17, "which can help clinicians identify ultra-metabolizers" of Plavix.

The Infiniti Analyzer, which was cleared by the FDA in 2007, has a menu of 42 applications, including 5 FDA-cleared products and 16 CE-marked products.

AutoGenomics is currently in waiting mode on its initial public offering, which was originally filed in 2008.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.